Comprehensive coverage on anti-mycobacterial endeavour reported during 2022

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a leading cause of death globally, exacerbated by drug resistance and increased prevalence in immunocompromised populations.
• The lengthy treatment duration for TB necessitates the development of novel anti-TB scaffolds.
• Previous reviews covered anti-mycobacterial scaffolds from 2015-2020, with an update in 2021.

Purpose of the Study:

• To provide insights into anti-mycobacterial scaffolds reported in 2022.
• To analyze the mechanism of action and structure-activity relationships (SAR) of these novel scaffolds.
• To offer key perceptions for designing next-generation anti-TB agents for medicinal chemists.

Main Methods:

• Comprehensive literature review of anti-mycobacterial scaffolds published in 2022.
• Analysis of reported mechanisms of action for identified scaffolds.
• Evaluation of structure-activity relationships to guide future drug design.

Main Results:

• Identification and summary of novel anti-mycobacterial scaffolds reported in 2022.
• Detailed insights into the mechanisms of action of these emerging anti-TB agents.
• Exploration of SAR to understand key structural features contributing to anti-mycobacterial activity.

Conclusions:

• The findings offer valuable perspectives on recent advancements in anti-TB drug discovery.
• Understanding SAR and mechanisms of action is crucial for developing effective new anti-TB therapies.
• This review serves as a resource for medicinal chemists focused on combating tuberculosis.